Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy PF-06939926

Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy PF-06939926

NEW YORK–(BUSINESS WIRE)–October 01, 2020 — Pfizer Inc. (NYSE: PFE) today announce...
read more
FDA approves first gene therapy for spinal muscular atrophy

FDA approves first gene therapy for spinal muscular atrophy

(HealthDay)—The first gene therapy has been appr...
read more
New muscular disease myoglobinopathy described

New muscular disease myoglobinopathy described

Researchers at the Bellvitge Biomedical Research I...
read more